Concurrent Chemoradiotherapy Outcomes in EGFR-Mutant Unresectable Stage III NSCLC
Posted: Monday, April 6, 2026
Concurrent chemoradiotherapy (cCRT) is the established standard of care for patients with unresectable stage III non–small cell lung cancer (NSCLC). However, it has remained unclear whether EGFR mutations serve as a reliable prognostic factor for the efficacy of this regimen. Previous research into cCRT for EGFR-mutated NSCLC often involved small sample sizes and yielded highly inconsistent results; some studies reported shorter progression-free survival, while others suggested that relapse occurred less frequently in these patients.
To resolve these contradictions, Shinkichi Takamori, MD, PhD, and colleagues conducted a comprehensive investigation using an integrated clinical trial database to compare efficacy and safety outcomes with cCRT between patients with and without these mutations, publishing the results in JTO Clinical And Research Reports.
The research team analyzed data from 274 patients—116 with EGFR mutations and 158 with EGFR wild-type status—drawn from three randomized phase II trials in Japan. They specifically evaluated outcomes such as objective response rate, progression-free survival, overall survival, and safety.
The results indicated that while patients with EGFR-mutant NSCLC who received cCRT had a significantly higher objective response rate than the wild-type group (75.0% vs 63.3%), this initial sensitivity did not lead to superior long-term control. Progression-free survival was significantly shorter in the EGFR-mutant group, with a median of 11.6 months compared to 12.2 months for those without an EGFR mutation. Interestingly, there was no significant difference in overall survival between the two groups, which researchers attributed to the frequent use of tyrosine kinase inhibitors after patients experienced a relapse.
Regarding the clinical significance of these findings, the study authors wrote, "Although patients with EGFR-mutant NSCLC had a significantly higher [objective response] to cCRT, they had significantly shorter [progression-free survival] than those with EGFR wild-type NSCLC, highlighting the potential limitations of cCRT."
Safety data also highlighted a critical concern: the incidence of severe (grades 3 or 4) pneumonitis was three times higher in the EGFR-mutant cohort, at 7.8%, compared to only 2.6% in the wild-type group. Consequently, the study authors concluded that while initial responses to cCRT among patients with EGFR-mutant NSCLC may be strong, the shorter progression-free survival and increased risk of lung toxicity associated with the regimen in this population underscore the need for maintenance therapies and meticulous monitoring during and after treatment.
DISCLOSURE: For full disclosures of all study authors, visit jtocrr.org
